The objective is to discuss the clinical experiences and outcomes associated with combining brentuximab-vedotin and bendamustine in relapsed or refractory Hodgkin lymphoma.
Analysis of real-world data from patients receiving brentuximab-vedotin and bendamustine for Hodgkin lymphoma.
Evaluation of treatment responses and outcomes.
Comparison with established clinical benchmarks.
The combination therapy demonstrates improved response rates in a real-world setting.
Patients experienced manageable adverse effects, enhancing quality of life.
Findings align with previous controlled clinical trial results, supporting the approach.